Total amount raised
$459.7 Million
Latest funding date
02/01/2022
Location
Synthego has successfully raised funds over nine rounds, with the latest being a Series E involving 11 investors. The company is backed by 29 investors, including AAF Management Ltd. and RA Capital Management.
Keep reading to explore the intricacies of Synthego's fundraising journey and the investors backing this innovative platform.
What Is Synthego?
Synthego is a genome engineering company based in Redwood City, California. Specializing in CRISPR gene editing and molecular diagnostics, the company aims to accelerate life science research and development.
Operating as a private entity, Synthego employs between 101 and 250 people. The company has been acquired by Perceptive Advisors and has raised funds through multiple rounds, with the latest being a Series E.
How Much Funding Has Synthego Raised?
- Seed Round
- Amount Raised: Not publicly disclosed
- Date: July 2012
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's operations and initial research.
- Debt Financing
- Amount Raised: USD 250,000
- Date: August 2012
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To secure additional working capital for early-stage development.
- Series A
- Amount Raised: USD 8,294,226
- Date: July 2013
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand research capabilities and develop initial product offerings.
- Series Unknown
- Amount Raised: CNY 1,000,000
- Date: August 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop and refine CRISPR technology.
- Series B
- Amount Raised: USD 41,000,000
- Date: January 2017
- Lead Investors: 8VC
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and enhance product development.
- Corporate Round
- Amount Raised: Not publicly disclosed
- Date: October 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To form strategic partnerships and collaborations.
- Series C
- Amount Raised: USD 110,000,000
- Date: October 2018
- Lead Investors: Founders Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the development of CRISPR-based tools and therapies.
- Series D
- Amount Raised: USD 100,000,000
- Date: August 2020
- Lead Investors: 8VC, RA Capital Management, Wellington Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the company's product portfolio and market reach.
- Series E
- Amount Raised: USD 200,000,000
- Date: February 2022
- Lead Investors: Perceptive Advisors
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the creation of a cell and gene therapy discovery and development ecosystem.
Total Amount Raised: USD 460,544,226. Current Valuation: Not publicly disclosed.
Key Investors
- Perceptive Advisors
- Details: Perceptive Advisors is a leading investment firm focused on the healthcare sector. They led Synthego's Series E financing round.
- Investment Focus Areas: Healthcare, life sciences.
- Notable Investments: Various biotech and pharmaceutical companies.
- 8VC
- Details: 8VC is a venture capital firm that invests in technology and life sciences companies. They were a lead investor in Synthego's Series B and Series D rounds.
- Investment Focus Areas: Technology, life sciences, healthcare.
- Notable Investments: Palantir, Wish, Guardant Health.
- RA Capital Management
- Details: RA Capital Management is a life sciences investment firm. They participated in Synthego's Series D and Series E rounds.
- Investment Focus Areas: Life sciences, healthcare.
- Notable Investments: Moderna, CRISPR Therapeutics, Beam Therapeutics.
- Wellington Management
- Details: Wellington Management is a global investment management firm. They participated in Synthego's Series D and Series E rounds.
- Investment Focus Areas: Broad range of sectors including healthcare, technology.
- Notable Investments: Alphabet, Amazon, Pfizer.
- Founders Fund
- Details: Founders Fund is a venture capital firm known for investing in transformative technology companies. They led Synthego's Series C round.
- Investment Focus Areas: Technology, healthcare, aerospace.
- Notable Investments: SpaceX, Facebook, Airbnb.
What's Next for Synthego?
With a fresh infusion of $200 million, Synthego is poised to revolutionize the field of CRISPR-based medicines. The company plans to accelerate the development of a cell and gene therapy discovery and development ecosystem, expanding the capabilities of its Halo and Eclipse Platforms. This significant financial backing underscores the vast opportunities available, particularly in advancing CRISPR technology and increasing GMP manufacturing capabilities.
Future fundraising efforts seem promising, especially with the strategic appointment of Avi Raval as CFO, who brings extensive experience in public and private financings. However, Synthego will need to navigate regulatory landscapes and maintain high standards of quality and efficacy to stay ahead in the rapidly evolving biotech sector.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Synthego and gather other critical business insights. Sign up for free and unlock the potential of data-driven decision-making today.
